NZ233560A - 2,3-bis(1h-indole-3-yl)-maleinimide derivatives; pharmaceutical compositions and preparation thereof - Google Patents

2,3-bis(1h-indole-3-yl)-maleinimide derivatives; pharmaceutical compositions and preparation thereof

Info

Publication number
NZ233560A
NZ233560A NZ233560A NZ23356090A NZ233560A NZ 233560 A NZ233560 A NZ 233560A NZ 233560 A NZ233560 A NZ 233560A NZ 23356090 A NZ23356090 A NZ 23356090A NZ 233560 A NZ233560 A NZ 233560A
Authority
NZ
New Zealand
Prior art keywords
preparation
bis
indole
pharmaceutical compositions
derivatives
Prior art date
Application number
NZ233560A
Inventor
Hubert Barth
Johannes Hartenstein
Claus Rudolph
Christoph Schachtele
Hans-Jurgen Betche
Hartmut Osswald
Reinhard Reck
Original Assignee
Goedecke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE3914764A external-priority patent/DE3914764A1/en
Priority claimed from DE19893942991 external-priority patent/DE3942991A1/en
Application filed by Goedecke Ag filed Critical Goedecke Ag
Publication of NZ233560A publication Critical patent/NZ233560A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Aerodynamic Tests, Hydrodynamic Tests, Wind Tunnels, And Water Tanks (AREA)
  • Image Processing (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)

Abstract

The invention relates to novel bis(1H-indol-3-yl)maleimide derivatives, a process for their preparation, pharmaceuticals containing these compounds and their use for the treatment of cardiac and vascular diseases such as thromboses, arteriosclerosis, hypertension, inflammatory processes, allergies, cancer and certain types of degenerative damage of the central nervous system and also disorders of the immune system and viral diseases.
NZ233560A 1989-05-05 1990-05-04 2,3-bis(1h-indole-3-yl)-maleinimide derivatives; pharmaceutical compositions and preparation thereof NZ233560A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3914764A DE3914764A1 (en) 1989-05-05 1989-05-05 New bis(1H-indol-3-yl) maleinimide derivs. - are inhibitors of protein kinase C for treatment of cardiovascular, CNS and immune system disorders
DE19893942991 DE3942991A1 (en) 1989-12-27 1989-12-27 New 2,3-bis:indolyl-maleimide derivs.

Publications (1)

Publication Number Publication Date
NZ233560A true NZ233560A (en) 1992-01-29

Family

ID=25880591

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ233560A NZ233560A (en) 1989-05-05 1990-05-04 2,3-bis(1h-indole-3-yl)-maleinimide derivatives; pharmaceutical compositions and preparation thereof

Country Status (16)

Country Link
EP (1) EP0397060B1 (en)
JP (1) JP2983248B2 (en)
KR (1) KR900018080A (en)
AT (1) ATE209202T1 (en)
AU (1) AU634541B2 (en)
CA (1) CA2015996C (en)
DE (1) DE59010927D1 (en)
DK (1) DK0397060T3 (en)
ES (1) ES2169719T3 (en)
FI (1) FI902251A0 (en)
HU (1) HU207727B (en)
IL (1) IL94274A0 (en)
NO (1) NO179748C (en)
NZ (1) NZ233560A (en)
PT (1) PT93947B (en)
YU (1) YU87990A (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89167A (en) * 1988-02-10 1994-02-27 Hoffmann La Roche Substituted pyrroles, their manufacture and pharmaceutical compositions containing them
DE4005970A1 (en) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh NEW TRISUBSTITUTED MALEINIMIDES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
JPH07504673A (en) * 1992-03-20 1995-05-25 ザ・ウエルカム・ファウンデーション・リミテッド Indole derivatives with antiviral activity
DE4243321A1 (en) * 1992-12-21 1994-06-23 Goedecke Ag Amino acid derivatives of heterocycles as PKC inhibitors
US5405864A (en) * 1993-10-15 1995-04-11 Syntex (U.S.A.) Inc. Chemotherapeutic maleimides
ES2134910T3 (en) * 1993-12-07 1999-10-16 Lilly Co Eli SYNTHESIS OF BISINDOLILMALEIMIDAS.
US5541347A (en) * 1993-12-07 1996-07-30 Eli Lilly And Company Synthesis of bisindolylmaleimides
US5843935A (en) * 1993-12-07 1998-12-01 Eli Lilly And Company Protein kinase C inhibitors
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
ES2162843T3 (en) * 1993-12-07 2002-01-16 Lilly Co Eli INHIBITORS OF PROTEIN QUINASA C.
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
DK0817627T3 (en) * 1993-12-23 2005-06-06 Lilly Co Eli Inhibitors of protein kinase C
ATE283863T1 (en) * 1994-05-09 2004-12-15 Banyu Pharma Co Ltd METHOD FOR PRODUCING INDOLOPYRROLOCARBAZOLE DERIVATIVES
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
US5559228A (en) * 1995-03-30 1996-09-24 Eli Lilly And Company Synthesis of bisindolylmaleimides
ATE191219T1 (en) * 1995-11-20 2000-04-15 Lilly Co Eli INTERMEDIATE PRODUCTS AND THEIR APPLICATION FOR THE PRODUCTION OF N,N'-BRIDGED BISINDOLYLMALEIMIDES
PE91598A1 (en) * 1996-07-29 1998-12-24 Hoffmann La Roche SUBSTITUTED PYRROLES
PE91498A1 (en) * 1996-07-29 1998-12-22 Hoffmann La Roche SUBSTITUTED PYRROLES
PE91698A1 (en) * 1996-07-29 1998-12-24 Hoffmann La Roche SUBSTITUTED PYRROLES
SE9603283D0 (en) * 1996-09-10 1996-09-10 Astra Ab New compounds
ES2212814T3 (en) * 1996-10-31 2004-08-01 Harbor Branch Oceanographic Institution, Inc. USE OF NEUROGENIC ANTI-INFLAMMATORY COMPOUNDS AND COMPOSITIONS.
AU2548699A (en) * 1998-02-23 1999-09-06 Rei Asakai Cell death inhibitors
CA2335254A1 (en) 1998-07-08 2000-01-20 Harbor Branch Oceanographic Institution, Inc. Bis-indole derivatives and their use as antiinflammatory agents
WO2000047575A1 (en) * 1999-02-09 2000-08-17 Sagami Chemical Research Center Pyrrole derivatives and cell death inhibitors
US6281356B1 (en) * 1999-12-22 2001-08-28 Hoffmann-La Roche Inc. Substituted pyrroles
CA2308994A1 (en) * 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
US7129250B2 (en) 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
DE10109280A1 (en) * 2001-02-26 2002-09-05 Peter Mayser Indole derivatives with inhibitory effects on protein kinases
TWI335221B (en) 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
TWI302836B (en) 2001-10-30 2008-11-11 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
CA2393720C (en) 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
US20060217368A1 (en) * 2003-04-18 2006-09-28 Kyowa Hakko Kogyo Co., Ltd. Drug for nerve regeneration
DK1846406T5 (en) 2005-02-09 2011-10-31 Arqule Inc Maleimide derivatives, pharmaceutical compositions and methods for the treatment of cancer
WO2009002806A1 (en) 2007-06-22 2008-12-31 Arqule, Inc. Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
CA2912546A1 (en) 2007-06-22 2008-12-31 Arqule, Inc. Compositions and methods for treatment of cancer
MX2009013815A (en) 2007-06-22 2010-03-01 Arqule Inc Quinazolinone compounds and methods of use thereof.
WO2010144780A1 (en) * 2009-06-12 2010-12-16 University Of Kansas Compositions and methods for establishing and maintaining stem cells in an undifferentiated state
EP3741375A1 (en) 2014-07-17 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating neuromuscular junction-related diseases
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4785085A (en) * 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
IL89167A (en) * 1988-02-10 1994-02-27 Hoffmann La Roche Substituted pyrroles, their manufacture and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
ES2169719T3 (en) 2002-07-16
NO179748C (en) 1996-12-11
EP0397060A3 (en) 1992-01-02
CA2015996A1 (en) 1990-11-05
HUT53902A (en) 1990-12-28
EP0397060A2 (en) 1990-11-14
YU87990A (en) 1992-07-20
JPH02306974A (en) 1990-12-20
AU634541B2 (en) 1993-02-25
IL94274A0 (en) 1991-03-10
DE59010927D1 (en) 2002-01-03
PT93947B (en) 1996-11-29
AU5466690A (en) 1990-11-08
KR900018080A (en) 1990-12-20
PT93947A (en) 1991-01-08
JP2983248B2 (en) 1999-11-29
NO901989L (en) 1990-11-06
NO179748B (en) 1996-09-02
NO901989D0 (en) 1990-05-04
HU207727B (en) 1993-05-28
HU902681D0 (en) 1990-09-28
EP0397060B1 (en) 2001-11-21
DK0397060T3 (en) 2002-05-21
CA2015996C (en) 2001-08-28
ATE209202T1 (en) 2001-12-15
FI902251A0 (en) 1990-05-04

Similar Documents

Publication Publication Date Title
NZ233560A (en) 2,3-bis(1h-indole-3-yl)-maleinimide derivatives; pharmaceutical compositions and preparation thereof
NO944564L (en) Indole carbazole imides and their use
ZA895969B (en) Alkoxy-4(1h)-pyridone derivatives,processes for the preparation thereof and pharmaceutical compositions containing them
EP0434057A3 (en) Indolocarbazole derivatives, processes for their preparation and their use
DE59300176D1 (en) 5,10-methylenetetrahydrofolic acid cyclodextrin inclusion compounds.
MY103593A (en) Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation
ZA898274B (en) 2-aminocarboxylic acids and their derivatives,processes for their preparation and their use as medicaments
ATE242766T1 (en) NEW DERIVATIVES OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES
DE69313534T2 (en) Digitoxigenin and dihydrodigitoxigenin 3-beta derivatives and pharmaceutical preparations thereof, for the treatment of hypertension